PuraCap The just in Until it of contract XXXX. are I'll the to you. summarize the excluding undergone change of management approval history The is required and binding pay that's that's the purchased us since that X.X of the expires change contents for still negotiating the problem get is been SequestOx We've they we contract. of It is with with SequestOx Puracab. has Company. Epic milestone valid. times million, the both if PuraCap management its that then, Okay, on regarding in us three
they it team. to we one team Epic changed recently the more their now and in else that then over had they somebody time. First, They management own changed taken brought
had FDA concern we've management discuss and how latest Tmax the Once hear study. Epic know and Our from the remains that with I'll the settled, the what FDA but react together statement. primary is. we with that first will one Pfizer's forward the answer pilot Troxyca. -- to we success the is about questions Question them need to to try about three path all can
not enter then product ago pediatric, the and extended-release and designated Pfizer's oxycodone work they Regarding till it and months did can three it. six launched else half years long for exclusivity was ER nobody a and the Pfizer as it discontinued. three have they've recently done launch quite years has market. Troxyca exclusivity, not for which approved Pfizer time
FDA even the is to product. market the to with determine, not to work So we we need when how get do making Pfizer
discontinue an and see cannot run to us need product. order went making their do that’s that. You If we they for study, straight a we BE it or not
get product the And that, that’s a that's the do make BE to know we figure not So chose be from we that market. they not us FDA FDA will do sure we path yet the how for product. answer into what to the need once do with to to to means entering stopping Pfizer you. but How answer provide and a market, are so is us we with out, discontinued. share run if to needs I'm the we work against to definitely effectively so, the able
questions, extended XX approvals were ago. months That's of average seem expect the begin accurate than to approvals the in one might have the beyond W On the future? for some of we approval to ANDA a When pipeline, fair, and filings Dr. added, can of and a more CRLs. time length question. Also, or couple good expect filings additional Elite generic
question we PDUFA rate a application date after on necessarily application. As least per XX even time the Then target starts then that a issue is that And them, and super own either, started approvals FDA it's give filings is a of when come a a new one on want then are because of issued themselves goal per the less and time that When year, maybe question is we minimum. letter, not attribute, one to stops me which and and clock PDUFA. but months the have length because that’s and to I plus and or with means their up, the next at a haven’t minor response PDUFA months, part fee about approval, takes a and clock answer ANDA question, if first I'll their ago, as to a their it fees meaning and that quarters. performance we this $XXX,XXX different the I quarter as back simple they month projected expect of okay. That part done, okay. four the to seen tracking way. examples. an let Congress file as achievement on us they I their complete To approved performance amendment respond. assessment. that they amendment per are the reporting for charging they and reviewing quarter or ANDA between address their the take a XX This my three ask obviously address ANDA again me give year schedule okay. issue can than say for for amendment, if come Then question, a major approvals, much they minor a you they that they on up the or PDUFA simple anything another And of with couple you time respond answer ask
minute could industry though it something a even by and to an up with in they the the back-and-forth that hope you with drags a are a we happening really drag are we and and And issues It that delays and give period us second. all that resources a are huge and obviously. is I’ll revising I So XX example that’s I'll our months, what X were really pay there fee loopholes application are becomes to on this we is doing. not evaluation be and we because counting But of because and exactly time. on that's you share specific hoping something a a minor have to thorough going within over in happening, what specific this
for give a of has a is on to When required to that Oxy APAP, case filed score of if things couple month of the examples. did that in in give half we what a see is one and we a let do, or the all companies stability is if a you So are me them product it put the and it the break wanted it, patient to required amount. pharmacist tablet you what
So with put filed issue that thought APAP should the and a it the what and that was to was of their chemist last fine With no and Oxy pharmacy, there that’s application it it. part they they month. it about in break review
that but the industry, and this done solution, the but go or she we few test the for repeat had never the months That second APAP, we a application we content and of the it the or have great was never feelings, not brand rejected, I recall wanted and them Hydro it application answer back do us to then the in same filed when and responded and because order later and put tablets of did thing. wanted if feelings more months, broke he exactly now So We to know heard you got only also sent us stopped, or chemist her and is them his they the before, one thing, that, inquiry. and ahead person and stability once to an three gave off ours themselves six in to went that then of they tested don’t them so that on they till them, us. that
need simple are these bond that So things but from some to break the little they not documents a you. application, really
respond Now, issue ask is think to time for. as simple very minimum months because for they is have as they a three they long the to the criteria you anything
year them up do the months document have respond, minute or a you to it But you okay. later, a give them even deliver it, can can give to minute. one minimum three them, to of to in give to it's once they you if it You to themselves
Another early encountered applications, impurities couple not of and in element issue required. were XXXX, with the
to what the application so were through magnesium done. of one back deficiency three of they sent course from saying take them the We took suppliers the us they of and impurities. to that stearate with we’ve that. ready exempt even were for And XXXX and of months While course this. came then of review did care they though went it We elemental now became provided required, with
to be decided not exempt go that everyone impurity product. should elemental perform and that FDA validation Somehow, ask this the the us only within industry, supplier not and on ahead specific the
big elemental impurities, the it's back-and-forth back-and-forth. not test So an the hire six deal to outside the lab a communication big about the that is and deal months. Even again to takes though,
to asking industry. all we the time addressed the try where shape stuff. hitting all hitting very it issues to situation, issues And me, they that partner target. and talking in what XX start say the is targeting -- with only FDA making to delay later what to database, to that when it’s filing the discussion has are they a preempt to approvals we’re matter these hitting frankly months the documents refusal, this the you, and say for a industry Whatever just us and and in more we’ve industry think and and our are database a just a of the it’s we’re we I remedy compiled the SunGen, XX good of we and
the it approved much a months things my we’ve of XXX%, than never the for under be spent expectation I that all the So coming especially is filed we before. of that recently, is think we’re ANDAs in because with, two rest do they’ll getting XX the be we’ve and of that studying less to lot closer were FDA new but we time it can these and that
really information next product One the additional transfer that, cost the profit a on. And of agreement? contacts the most about price. make cover a worked as Your favorable two sharing was, things of is, we plus We add. Glenmark question I’ll we second the all is the that’s provide will
we’re the very happy So with Glenmark.
we to year. Next already approve-and-launch-launch-launch. still and SunGen focus set We’ve really filed year to slow maybe and this we’ve to I to next January, I SunGen. with we’re year. our will so we this that. a December, launch. start covered that next of question already bit year SunGen may hoping the the down Two that of five over we shifting am have be from do will by much is next Two I need going the is one update more this the say. what and products with end the to on We’ve And on from products year year. file-file-file file SunGen. of really be work need
half the ANDA we’ve an every to ago, we’re As promised quarter stop year filing you and and going doing it. been about
week. spoke on We were technology with a on patent CC? patent Can file technology that on plan? This and clinical this about you study. focuses art the during two two Now, you’re shift all we’re IR the pilot the Were going that find products for plan technology a do failed? launching technology big to the product platform pharmacological of information ANDAs anti-abuse has speaking approach, unique to nothing was always in backup actually the The genetics okay. week we’re unique creating you It's start they case additional a different filed provide last that last art big okay. last a The technology, regarding Or or opioids. into Elite’s quarter. every these art
exciting this So technology. is an
Elite. I It valuation, We to billion at an still Octobot not on order the Nasrat, you to Do answer one plan it's totally land, will work such for would about to reach technology. as two example trial can but the okay. the product $X Last once arena in wanted And Elite different stock our a have on Company from you to for fund. is question price eventually SunGen. give this the big evaluation? clinical take question. that Elite dollar shows revenues already update the you be absolutely, a worth is is definitely with systems I feel confident more to anti-abuse dedication yes. generate get we the better will phase, more
these there don't dollar that we with Elite bigger much when product would of launch to another very get SunGen, two in land. alone reach doesn't one. order revenue, so us that this have We easily. that we than have we're The combination that’s them and much partnering
a million $XX and okay. X we billion on dollar outstanding already a at billion the shares XX whenever in share, PE So generate a dollar of profit you’re ready valuation,
quarter really that salary, quarter to taxes XX% the money are three it. stocks. is do is a on restricted it. certificate in except in pay that Elite's the number so a paycheck in stocks that stockholder. absolutely in I Elite had in IRS paid issues time XX% to have have in stocks restricted stocks to outstanding company believed pay much I on that paycheck. it was have on cash, pays It’s always not paying case, am something Elite's been for me have that and this have I never I seen, I I stock guest a me years. taxes So, so I okay. and Every single I I not as one company believe getting truly I of I gives them the we we’re get our paid Thank And my believe solid cash call. and care have me believe And foundation listening. conclude from a justify you, have unless created believe take that two I earnings IRS all that and I will to in money. to days truly today great evaluation. the still Elite's going away five have Catharine, And you counted Thank to family weekend. business the years. Today, Elite. fundamentals for I'm have give that week because do to a a we note, there on dollars in less for earnings and live I and billion stocks. in than have to
